Saturday, July 29, 2017 8:35:08 AM
anti-CTLA-4 antibody developers?
AZ’s Tremelimumab is an IgG2 antibody which has a different mechanism of action than
IgG1 anti-CTLA-4 antibodies.
The only approved anti-CTLA-4 antibody is BMS’s Yervoy®, which is an IgG1.
Agenus’ anti-CTLA-4 antibody, which is currently in clinical development is also an
IgG1.
We see the MYSTIC trial negative result as a positive for Agenus for the following
reasons:
• Other than Yervoy, AGEN1884 is the most clinically advanced anti-CTLA-4
antibody that has a differentiated mechanism of action as compared to
Tremelimumab.
• It has been shown that an IgG1 anti-CTLA-4 antibody provides more than just
blockade of the CTLA-4 receptor. In addition to blocking CTLA-4, AGEN1884
promotes FcyR-dependent anti-tumor mechanisms which is expected to provide
superior therapeutic benefit to IgG2 antibodies.
• In BMS’ checkmate trial, the combination of Opdivo™ (anti-PD-1) and Yervoy
(anti-CTLA-4) in advanced non–small cell lung cancer (NSCLC) resulted in a
PFS that was double that observed with Opdivo alone. If the follow-up
Checkmate 227 trial confirms these results, it would further confirm the superior
efficacy of the IgG1 format. Again, supporting the rationale for AGEN1884 value
in combinations.
Agenus' IgG1 anti-CTLA-4 antibody (AGEN1884) clinical development plan is
advancing, with increased potential to be second to market.
• Agenus’ anti-CTLA-4/PD-1 combination dosing schedule will be consistent with
what has been used in previous successful clinical trials.
• The potential for targeting CTLA-4 remains unrealized, including to enable future
immuno-oncology combinations, when paired with the right molecule, including
vaccines.
CTLA-4 remains attractive for future Agenus I-O combinations
In summary, we believe that the value of our anti-CTLA-4 antibody is supported by
underlying scientific rationale – importantly, biological advantages of an IgG1 vs IgG2
backbone and prior clinical validation remains intact.
We will be providing an update on Agenus at our Q2 earnings call on August 3, 2017,
and invite you to join for information on the company and a Q&A. You can access
information about the Q2 call and webcast here.
Contact:
Agenus Inc.
Michael Plater
781-674-4504
michael.plater@agenusbio.com
SOURCE Agen
Recent AGEN News
- The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/23/2024 09:45:00 AM
- Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN) • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 • Business Wire • 09/13/2024 02:00:00 PM
- Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/11/2024 06:25:00 PM
- Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 • Business Wire • 09/09/2024 11:30:00 AM
- Agenus to Participate in September Investor Conferences • Business Wire • 09/03/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:49:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:47:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:08:46 PM
- Agenus Reports Second Quarter 2024 Operational and Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Announces Appointment of Tom Harrison to Board of Directors • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers • Business Wire • 08/07/2024 02:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:02:09 PM
- Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update • Business Wire • 07/26/2024 11:00:00 AM
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM